Previous 10 | Next 10 |
home / stock / zldpf / zldpf news
Press Release - No. 17/2018 Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA) Low doses of dasiglucagon effectively counteract low blood glucose in people with type 1 diabetes Long-t...
Press Release - No. 16/2018 Survey demonstrating underuse of glucagon rescue kits in type 1 diabetes patients to be presented at the ADA's 78th Scientific Sessions T1D Exchange and Dr. Morey Haymond, MD, to present a Zealand Pharma supported survey of use of glucagon rescue k...
The first of two Phase 3 clinical trials assessing Zealand Pharma's ( OTCPK:ZLDPF ) dasiglucagon for the rescue treatment of severe hypoglycemia (low blood sugar) in type 1 diabetics met the primary and key secondary endpoints. More news on: Zealand Pharma A/S, Novo Nordisk A/S, Healthca...
Press release - No. 15/2018 Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes The results of the first of two completed Phase 3 trials confirm dasiglucagon's safety and efficacy profile in patients w...
Press Release - No. 14/2018 Z ealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S. The results demonstrates glepaglutide's effects on intestinal transit time, morphology and energy a...
Press release - No. 13 / 2018 Zealand Pharma will attend the Jefferies Global Healthcare Conference on June 5-8, 2018 in New York Copenhagen, May 31, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will attend the Jefferies Globa...
Company announcement - No. 17/2018 Zealand announces amendments to its Articles of Association following the granting of warrants Copenhagen, May 31, 2018 - Zealand Pharma ("Zealand") announces that its Articles of Association have been amended to reflect the recent grant of warra...
Company Announcement - No. 16/2018 Zealand Pharma reports completion of the second and pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia Last patient visit concluded in the multinational pivotal Phase 3 trial ahead of previous guidance, w...
The following slide deck was published by Zealand Pharma A/S in conjunction with their 2018 Q1 earnings Read more ...
Zealand Pharma A/S (ZLDPF) Q1 2018 Results Earnings Conference Call May 16, 2018, 10:00 am ET Executives Britt Meelby Jensen - President and Chief Executive Officer Mats Blom - Executive Vice President and Chief Financial Officer Adam Steensberg - Executive Vice President, Chief ...
News, Short Squeeze, Breakout and More Instantly...
Zealand Pharma A/S Ord Company Name:
ZLDPF Stock Symbol:
OTCMKTS Market:
Zealand Pharma A/S Ord Website:
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE U...
Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO T...
Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CAN...